{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:30:34Z","timestamp":1788363034591,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["22-ALG-04 M4"],"award-info":[{"award-number":["22-ALG-04 M4"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["22-ALG-04 M4"],"award-info":[{"award-number":["22-ALG-04 M4"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["22-ALG-04 M4"],"award-info":[{"award-number":["22-ALG-04 M4"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["22-ALG-04 M4"],"award-info":[{"award-number":["22-ALG-04 M4"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10133-5","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T04:03:38Z","timestamp":1730779418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales"],"prefix":"10.1186","volume":"24","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Kimbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"2","key":"10133_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","volume":"46","author":"JF Timsit","year":"2020","unstructured":"Timsit JF, Ruppe E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020;46(2):266\u201384.","journal-title":"Intensive Care Med"},{"issue":"2","key":"10133_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jinf.2016.11.001","volume":"74","author":"C Adrie","year":"2017","unstructured":"Adrie C, Garrouste-Orgeas M, Ibn Essaied W, Schwebel C, Darmon M, Mourvillier B, et al. Attributable mortality of ICU-acquired bloodstream infections: impact of the source, causative micro-organism, resistance profile and antimicrobial therapy. J Infect. 2017;74(2):131\u201341.","journal-title":"J Infect"},{"issue":"1","key":"10133_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","volume":"13","author":"F Barbier","year":"2023","unstructured":"Barbier F, Hraiech S, Kerneis S, Veluppillai N, Pajot O, Poissy J, et al. Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Ann Intensive Care. 2023;13(1):65.","journal-title":"Ann Intensive Care"},{"issue":"10","key":"10133_CR4","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-beta-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):e00397\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10133_CR5","doi-asserted-by":"publisher","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","volume":"10","author":"HS Sader","year":"2023","unstructured":"Sader HS, Mendes RE, Carvalhaes CG, Kimbrough JH, Castanheira M. Changing epidemiology of carbapenemases among carbapenem-resistant enterobacterales from United States hospitals and the activity of aztreonam-avibactam against contemporary Enterobacterales (2019\u20132021). Open Forum Infect Dis. 2023;10(2):ofad046.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10133_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019;79(3):271\u201389.","journal-title":"Drugs"},{"issue":"6","key":"10133_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","volume":"11","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI, Cefiderocol. Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiot (Basel). 2022;11(6):723.","journal-title":"Antibiot (Basel)"},{"issue":"5","key":"10133_CR8","doi-asserted-by":"publisher","first-page":"e0150522","DOI":"10.1128\/aac.01505-22","volume":"67","author":"C Lasarte-Monterrubio","year":"2023","unstructured":"Lasarte-Monterrubio C, Guijarro-Sanchez P, Vazquez-Ucha JC, Alonso-Garcia I, Alvarez-Fraga L, Outeda M, et al. Antimicrobial activity of cefiderocol against the carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with metallo-beta-lactamase VIM-1. Antimicrob Agents Chemother. 2023;67(5):e0150522.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10133_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"HS Sader","year":"2018","unstructured":"Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015\u20132016. Diagn Microbiol Infect Dis. 2018;92(1):69\u201374.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10133_CR10","unstructured":"CLSI. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA, 2018."},{"issue":"3","key":"10133_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, Cisneros JM, Torre-Cisneros J, Rodriguez-Hernandez MJ, Tallon-Aguilar L, Calbo E, et al. Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020;75(3):618\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"10133_CR12","unstructured":"CLSI. M100Ed33. Performance standards for antimicrobial susceptibility testing: 33nd informational supplement. Wayne, PA, 2023."},{"key":"10133_CR13","unstructured":"FDA. US FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria"},{"key":"10133_CR14","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters [Internet]. European Committee on Antimicrobial Susceptibility Testing. 2023. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.0_Breakpoint_Tables.pdf"},{"issue":"5","key":"10133_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1089\/cmb.2012.0021","volume":"19","author":"A Bankevich","year":"2012","unstructured":"Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455\u201377.","journal-title":"J Comput Biol"},{"issue":"1","key":"10133_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2019.296","volume":"41","author":"LM Weiner-Lastinger","year":"2020","unstructured":"Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015\u20132017. Infect Control Hosp Epidemiol. 2020;41(1):1\u201318.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10133_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2022.06.018","volume":"30","author":"GM Rossolini","year":"2022","unstructured":"Rossolini GM, Stone G, Kantecki M, Arhin FF. In vitro activity of aztreonam\/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019. J Glob Antimicrob Resist. 2022;30:214\u201321.","journal-title":"J Glob Antimicrob Resist"},{"key":"10133_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jgar.2023.12.027","volume":"36","author":"GM Rossolini","year":"2023","unstructured":"Rossolini GM, Arhin FF, Kantecki M. In vitro activity of aztreonam-avibactam and comparators against metallo-beta-lactamase-producing enterobacterales from ATLAS Global Surveillance Program, 2016\u20132020. J Glob Antimicrob Resist. 2023;36:123\u201331.","journal-title":"J Glob Antimicrob Resist"},{"key":"10133_CR19","doi-asserted-by":"crossref","unstructured":"Sader HS, Carvalhaes CG, Kimbrough JH, Mendes RE, Castanheira M. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020\u20132022). Int J Antimicrob Agents. 2024:107113.","DOI":"10.1016\/j.ijantimicag.2024.107113"},{"issue":"3","key":"10133_CR20","doi-asserted-by":"publisher","first-page":"107081","DOI":"10.1016\/j.ijantimicag.2023.107081","volume":"63","author":"S Mushtaq","year":"2024","unstructured":"Mushtaq S, Vickers A, Woodford N, Livermore DM. Activity of aztreonam\/avibactam and ceftazidime\/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. Int J Antimicrob Agents. 2024;63(3):107081.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10133_CR21","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1093\/jac\/dkab279","volume":"76","author":"RE Mendes","year":"2021","unstructured":"Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS, Castanheira M. Investigation of mechanisms responsible for decreased susceptibility of aztreonam\/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. 2021;76(11):2833\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10133_CR22","doi-asserted-by":"publisher","first-page":"e01659","DOI":"10.1128\/AAC.01659-20","volume":"64","author":"M Sadek","year":"2020","unstructured":"Sadek M, Juhas M, Poirel L, Nordmann P. Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-beta-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother. 2020;64(12):e01659\u201320.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10133-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:03:53Z","timestamp":1730819033000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10133"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10133-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4254052\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not include factors necessitating patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1242"}}